

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included, which are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise the ADTC on their preferred medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

<p>Atezolizumab infusion Tecentriq® SMC2349</p>	<p>In combination with bevacizumab for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>09/08/2021</p>
<p>Autologous anti-CD19-transduced CD3+ cells infusion Tecartus® SMC2351</p>	<p>Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.</p>	<p>Routinely available in line with national guidance</p>	<p>09/08/2021</p>
<p>Avatrombopag tablets Doptelet® SMC2345</p>	<p>Treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids or immunoglobulins).</p>	<p>Routinely available in line with national guidance</p>	<p>09/08/2021</p>
<p>Avelumab infusion Bavencio® SMC2359</p>	<p>Monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>09/08/2021</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p>Bempedoic acid tablets Nilemdo® SMC2363</p>	<p>Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - In combination with a statin, or a statin with other lipid-lowering therapies in patients unable to reach low-density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or -Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contra-indicated.</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 01/02/2022</p>	
<p>Delafloxacin infusion, tablets Quofenix® SMC2393</p>	<p>Treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	09/08/2021
<p>Elotuzumab infusion Empliciti® SMC2407</p>	<p>In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	09/08/2021
<p>Fampridine tablet Fampyra® SMC2253</p>	<p>Improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7).</p>	<p>Routinely available in line with local or regional guidance</p>	09/08/2021

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Fostemsavir MR tablets Rukobia® SMC2389	In combination with other antiretrovirals for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.	Not routinely available as not recommended for use in NHSScotland	09/08/2021
Guselkumab injection Tremfya® SMC2360	alone or in combination with methotrexate (MTX) for the Treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.	Routinely available in line with national guidance	09/08/2021
Imipenem/ cilastatin/ relabactam infusion Recarbrio® SMC2390	Treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.	Not routinely available as not recommended for use in NHSScotland	09/08/2021
Inclisiran injection Leqvio® SMC2358	Treatment for adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients who are unable to reach LDL-C goals with the maximum tolerated dose of a statin, or - alone or in combination with other lipid lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 01/02/2022	09/08/2021

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p>Nivolumab infusion</p> <p>Opdivo®</p> <p>SMC2362</p>	<p>Monotherapy for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>09/08/2021</p>
<p>Ofatumumab pre-filled syringe/ pen</p> <p>Kesimpta®</p> <p>SMC2357</p>	<p>Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>09/08/2021</p>
<p>Olaparib tablets</p> <p>Lynparza®</p> <p>SMC</p>	<p>Monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>09/08/2021</p>
<p>Patiromer oral suspension</p> <p>Veltassa®</p> <p>SMC2381</p>	<p>Hyperkalaemia in adults</p>	<p>Routinely available in line with national guidance</p>	<p>09/08/2021</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p>Pertuzumab and trastuzumab injection Phesgo® SMC2364</p>	<p>1) Early breast cancer (EBC) In combination with chemotherapy in: - the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence - the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence 2) Metastatic breast cancer (MBC) In combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.</p>	Routinely available in line with local or regional guidance	09/08/2021
<p>Tafamidis capsules Vyndaqel® SMC2354</p>	Treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).	Not routinely available as not recommended for use in NHSScotland	09/08/2021
<p>Volanesorsen injection Waylivra® SMC2299</p>	As an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.	Routinely available in line with national guidance	09/08/2021